UK Medicines Information
New product: Kanjinti (biosimilar trastuxumab)
Information type:
Drug prescribing
Source:
electronic Medicines compendium
Specialities:
Cardiovascular system disorders | Gastrointestinal disorders
Summary
Kanjinti (biosimilar trastuzumab) is licensed for the treatment of HER2+ve early and metastatic breast cancer, and HER2+ve metastatic gastric cancer.
UKMi comment
The European Medicines Agency confirm that it is highly similar to the reference product Herceptin (trastuzumab) and has comparable quality, safety and efficacy.
Related links: